Performance of the MAGGIC heart failure risk score and its modification with the addition of discharge natriuretic peptides

Mitsuaki Sawano1, Yasuyuki Shiraishi1, Shun Kohsaka1*, Toshiyuki Nagai2,3,9, Ayumi Goda5, Atsushi Mizuno4, Yasumori Sujino6, Yuji Nagatomo7,8, Takashi Kohno1, Toshihisa Anzai2,9, Keiichi Fukuda1 and Tsutomu Yoshikawa7

1Department of Cardiology, Keio University School of Medicine, Tokyo, Japan; 2Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan; 3National Heart and Lung Institute, Imperial College London, London, UK; 4Department of Cardiology, St Luke’s International Hospital, Tokyo, Japan; 5Division of Cardiology, Kyorin University School of Medicine, Tokyo, Japan; 6Department of Cardiology, Saitama Medical University International Medical Center, Saitama, Japan; 7Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan; 8Department of Cardiology, National Defense Medical College; 9Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine

Abstract

Aims Predictive models for heart failure patients are widely used in the clinical practice to stratify patients’ mortality and enable clinicians to tailor and intensify their approach. However, such models have not been validated internationally. In addition, biomarkers are now frequently measured to obtain prognostic information, and the implications of this practice are not known. In this study, we aimed to validate the model performance of the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) score in a Japanese acute heart failure registry and further explore the incremental prognostic value of discharge B-type natriuretic peptide (BNP) level.

Methods and Results In this study, we evaluated the registered data of 2215 consecutive acute HF patients (with 694,119 person-years follow-up) from a prospective multicentre registry (the West Tokyo Heart Failure) conducted in Japan from April 2006 to August 2016. The mean age was 73.0 ± 13.0, and 61.2% were male. The MAGGIC score demonstrated modest discrimination (c-index = 0.71, 95% confidence interval 0.67–0.74) and good calibration ($R^2$ value = 0.97); there was constant overestimation for 1 year mortality. However, when the BNP level was added to the original MAGGIC variables, the model demonstrated good discrimination (c-index = 0.74, 95% confidence interval 0.70–0.78) with adequate calibration ($R^2$ value = 0.91). The modified MAGGIC BNP score was externally validated in a separate Japanese registry (NaDEF) and demonstrated moderate discrimination (c-index = 0.69, 95% confidence interval 0.65–0.73) and calibration ($R^2$ value = 0.85).

Conclusion The original MAGGIC score performed modestly in Japanese patients, but the addition of discharge BNP level enhanced model performance. The addition of objective biomarkers may result in effective modification of preexisting internationally recognized risk models and aid in multinational comparisons of heart failure patients’ outcomes.

Keywords Heart failure; Prediction; Validation; East Asia

Received: 12 October 2017; Revised: 27 January 2018; Accepted: 1 February 2018
*Correspondence to: Shun Kohsaka, Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. Tel: +81 3 5843 6702; Fax: +81 3 5363 3875. Email: sk@keio.jp

Introduction

Heart failure (HF) is a growing epidemic worldwide particularly in countries with a rapidly ageing population.1 In Japan, with over 10.5 million octogenarians at present, the number of HF patients is expected to grow proportionately over the coming decades. To best identify patients at risk and concentrate limited resources, high-performing internationally validated risk prediction models are necessary.2 Predicting 1 year mortality in HF patients has become extremely important in order to stratify patients that require...
Performance of the MAGGIC score among Japanese patients

Methods

Study population

In this study, two registries were used as derivation and validation cohorts for evaluating the performance of the prediction models. The derivation cohort was the West Tokyo Heart Failure (WET-HF) registry, and the validation cohort was the National Cerebral and Cardiovascular center acute DEmcompensated heart Failure study (NaDEF). In both registries, acute HF was defined as rapid-onset HF or a change in the signs and symptoms of HF requiring urgent therapy and hospitalization, based on the Framingham criteria.11 HF patients presenting with coexisting acute coronary syndrome were not included because of exclusion criterion. Individual cardiologists at each institution made the clinical diagnosis of HF. The institutional review boards at each site approved the study protocol, and research was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each subject before the study.

The derivation cohort was the WET-HF registry: a large, ongoing, prospective, multicenter cohort registry conducted in Tokyo, Japan (East Japan), from June 2005 to August 2016. Details of the registry have been described previously.12–15 Dedicated clinical research coordinators collected clinical data by reviewing individual patient medical records. Exclusive on-site auditing by the investigators (Y.S. and S.K.) ensured proper registration of each patient. The objectives and detailed design are provided on the University Hospital Medical Information Network (UMIN000001171).

The validation cohort for our study was the NaDEF study: an ongoing, prospective, single-centre acute HF registry conducted at the National Cerebral and Cardiovascular Center in Osaka, Japan (West Japan), that began from January 2013. The objectives and detailed design are provided on the University Hospital Medical Information Network (UMIN000017024).16,17

Patient selection and calculation of the MAGGIC score

Patients were excluded for missing data required for calculation of the MAGGIC score (Figure 1). The 1 year mortality rate was calculated using the MAGGIC score including 13 clinical variables: age, ejection fraction as categorical variable (≥40%, 35–39%, 30–34%, 25–29%, <20%), New York Heart Association (NYHA) functional class, serum creatinine, diabetes, non-prescription of beta-blocker, systolic blood pressure (SBP), body mass index, time since diagnosis, current smoker, chronic obstructive pulmonary disease, male gender, and non-prescription of angiotensin-converting enzyme inhibitor or angiotensin receptor blockers for the remaining patients. Discharge NYHA class status was imputed as NYHA class II for 187 (8.4%) of the patients with missing data. Data on time since first diagnosis of HF or HF duration were not collected in our current database; thus, patients with previous history of HF hospitalization were regarded as having HF duration of more than 18 months. The study population was divided into six risk categories (Groups 1–6) based on the MAGGIC score according to the original article.5

Statistical analysis

The patient demographics, the predicted cardiovascular death risk according to the MAGGIC score, and the observed mortality rate were compared between those who died during the first year of follow-up and those who did not by using the Student’s t-tests or the Wilcoxon rank-sum test for continuous variables and χ² test for categorical variables.

Time-to-event data were calculated as the time in days from the date of discharge after initial hospitalization for acute HF to the date of all-cause death. Cumulative survival was computed according to the Kaplan–Meier method. We
fit a Cox regression model with the calculated MAGGIC score as the only independent variable, and we calculated the c-index, which is regarded as a measure for model discrimination equivalent to the area under curve for binary dependent variables. A c-index equal or above 0.6 was considered modest, a c-index above 0.7 was considered reasonable, and a c-index above 0.80 was considered strong. Receiver operating characteristic curves were computed by using the MAGGIC score as the reference variable and the 1 year observed mortality as the binary reference variable, and the area under the receiver operating characteristic curve were calculated. To measure model calibration, we compared the predicted mortality rate to the observed mortality rate on the calibration plot and evaluated the coefficient of determination ($R^2$ value). Further, we compared the regression line drawn within the plotted points to the line of unity and calculated the best fit linear regression formula according to the observed mortality rate.

The modified MAGGIC score was created by adding the log-transformed discharge BNP value as an ordinal covariate and incorporated along with the MAGGIC score as independent variables and 1 year mortality rate as the dependent variable. We evaluated model discrimination and calibration similarly as stated previously. Model improvement was assessed by the Akaike information criterion (AIC) and Bayesian information criterion (BIC). Furthermore, the modified MAGGIC score was further evaluated in an independent Japanese HF cohort for external validation of the newly created risk prediction model. Model discrimination and calibration were evaluated similarly as stated previously. All statistical analyses were performed by Stata/IC version 13.1 for Macintosh (StataCorp, College Station, TX).

**Results**

**Patient demographics**

Overall, 2215 consecutive acute HF patients (with 694 119 person-years follow-up) in the WET-HF registry were evaluated in this study. In brief, the mean age was 73.1 ± 13.5, 62.3% ($n = 1136$) were male, mean body mass index was 23.3 ± 4.4, 43.9% had a left ventricular ejection fraction below 40%, mean SBP upon admission was 139 ± 34 mmHg, creatinine level was 127 ± 26 μmol/L, 32.3% ($n = 572$) had a previous history of HF admissions, 25.5% ($n = 459$) had an ischaemic aetiology for HF, and the median discharge BNP level was 248 μg/dL (Q1–3, 129–528 μg/dL) (Table 1 and 2). The study patients were divided into those who were alive or dead after 1 year of follow-up. Patients who died ($n = 178$) were older, leaner, had a lower SBP, haemoglobin level, and sodium level, higher creatinine, proportion of cardiac resynchronization therapy insertion, HF with ischaemic aetiology, and discharge BNP with longer length of stay during the initial hospitalization.

The MAGGIC score was available for 2215 patients with a median score of 25 points with the first (Q1) and third (Q3) interquartile ranging from 21 to 29 points (Figure 2). The overall predicted median 1 year mortality rate was 16.0%. Patients who survived ($n = 1974$) had a median score of 25 (20–28) points (predicted mortality rate, 19.1%), and those who died ($n = 241$) had a median score of 29 (25–33) points (predicted mortality rate, 22.7%), respectively. A Kaplan–Meier mortality curve has been drawn for the six risk categories divided by the MAGGIC score displaying a distinct difference in 1 year mortality (log-rank $P < 0.001$: Figure 3).
Within the WET-HF study population, the MAGGIC score demonstrated modest discrimination (c-index = 0.71, 95% confidence interval 0.67–0.74) and good calibration ($R^2$ value = 0.96) (Figure 4A,B) with a constant overestimation throughout all six risk groups for 1 year mortality (Supporting Information, Figure S1). The regression formula drawn linearly on the calibration plot was as follows:

$$\text{Observed 1 year mortality} = 0.0417 + 0.9095 \times \text{Predicted 1 year mortality}.$$  

When discharge BNP level was added to the MAGGIC score, the modified model demonstrated improved discrimination (c-index = 0.74, 95% confidence interval 0.70–0.78) and good calibration ($R^2$ value = 0.91). The AIC and BIC for the original MAGGIC score (AIC = 1413.818, BIC = 1425.224) improved after modification (AIC = 862.454, BIC = 878.1867). The regression formula drawn linearly on the calibration plot was as follows (Figure 4C,D):

$$\text{Observed 1 year mortality} = 0.0032 + 0.9166 \times \text{Predicted 1 year mortality}.$$  

Finally, the modified MAGGIC score was externally validated in an independent HF registry cohort (NaDEF registry). The modified model demonstrated modest discrimination (c-index = 0.69; 95% confidence interval, 0.65–0.73) and good calibration ($R^2$ value = 0.85) (Figure 5). Similarly, the AIC and BIC for the original MAGGIC score (AIC = 369.0387, BIC = 377.7717) improved after modification (AIC = 344.7423, BIC = 353.4195) within the NaDEF registry, as well.

### Discussion

To our knowledge, this is the first reporting of an extensive external validation of the MAGGIC score outside the European states. In this Japanese HF registry, the MAGGIC score...
demonstrated modest discrimination and calibration with a constant overestimation upon risk prediction of 1 year mortality. To our knowledge, this is the first reporting of an extensive external validation of the MAGGIC score outside the European states. Additionally, when discharge BNP was added to the MAGGIC score, the modified risk model demonstrated improved discrimination without lowering calibration that was further confirmed by external validation in an independent HF registry cohort. These results demonstrate that the original MAGGIC score can modestly predict 1 year mortality, but the addition of BNP greatly enhances its performance, thereby re-emphasizing the importance of the prognostic impact given by discharge BNP levels in Japanese HF patients. These findings suggest that the addition of objective biomarkers may result in effective modification of preexisting internationally recognized risk prediction models and multinational comparisons of HF patients’ outcomes.

Previously, we reported the performance of two HF risk models that are widely used in the Western HF community: the Seattle Heart Failure Model and the Get With The Guideline Heart Failure risk score within the Japanese HF population. While the Get With The Guideline–Heart Failure risk score was designed to give estimates on short-term inhospital mortality, the Seattle Heart Failure Model predicts long-term post-discharge 1 and 2 year mortality similar to the MAGGIC score. Notably, the Seattle Heart Failure Model demonstrated modest performance with a c-index of 0.666 and 0.721, respectively, in a subset of 492 Japanese HF patients. Although the Seattle Heart Failure Model demonstrated modest performance, it does have its own disadvantages. The calculation of the Seattle Heart Failure Model requires only clinically routinely collected variables and also gives predictions on 1 and 3 year mortality, it has its advantages over the Seattle Heart Failure Model, thus requires rigorous validation in other ethnicities from around the globe.

Table 2  Extent of missing data

| Parameter                          | n  | %  |
|------------------------------------|----|----|
| Age (years)                        | 0  | 0.0|
| Male, %                            | 0  | 0.0|
| BMI (kg/m²)                        | 148| 6.7|
| EF, %                              | 0  | 0.0|
| EF < 40%                           | 0  | 0.0|
| Previous heart failure admission   | 0  | 0.0|
| Atrial fibrillation                | 129| 5.8|
| Medical history, %                 | 0  | 0.0|
| Diabetes, %                        | 0  | 0.0|
| Hypertension, %                    | 5  | 0.2|
| Stroke, %                          | 7  | 0.3|
| Current smoker, %                  | 0  | 0.0|
| COPD, %                            | 0  | 0.0|
| Length of stay, days               | 3  | 0.14|
| Systolic BP (mmHg)                 | 6  | 0.3|
| NYHA class, %                      | 187| 8.4|
| I                                  |    |    |
| II                                 |    |    |
| III                                |    |    |
| IV                                 |    |    |
| Haemoglobin (g/L)                  | 3  | 0.1|
| Creatinine (mg/dL)                 | 0  | 0.0|
| BUN (mg/dL)                        | 67 | 3.0|
| Sodium (mmol/L)                    | 4  | 0.2|
| BNP (pg/mL)                        | 815| 36.8|
| Medications, %                     |    |    |
| ACE inhibitor, %                   | 0  | 0.0|
| ARB, %                             | 0  | 0.0|
| Beta-blocker, %                    | 0  | 0.0|
| Aldosterone antagonist, %          | 8  | 0.4|
| Loop diuretics, %                  | 0  | 0.0|
| Digoxin, %                         | 0  | 0.0|
| MAGGIC score                       | 0  | 0.0|

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BMI, body mass index; BP, blood pressure; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; MAGGIC, Meta-analysis Global Group in Chronic Heart Failure; NYHA, New York Heart Association.

Figure 2  Distribution of the MAGGIC score within the WET-HF registry.

![Figure 2](image_url)
Several distinct differences between the MAGGIC study population and the WET-HF registry have been noted. Within the 31 studies utilized to create the MAGGIC study, six studies mostly conducted during the 1990s (DIAMOND, DIG, CHARM, and ECHOS trials and IN-CHF and HOLA registries) contributed to over three quarters of the entire meta-analysis population and were larger or equal to the population size of our current study population. Despite showing a similar distribution in the baseline MAGGIC scores, the observed mean mortality rate was lower than the predicted mortality rate in our database. A similar trend was observed in the external validation European cohort as well. Two main reasons could have affected this trend: (i) a disproportionately high score appointed to one or more variables used to calculate the MAGGIC score or (ii) an important prognostic factor not incorporated in the MAGGIC score. An example for the first reason is ejection fraction, and examples for the second reason are renal function (e.g. blood urea nitrogen and/or glomerular filtration rate), serum sodium level, exercise capacity, and frailty. Other unmeasured covariates such as the intensity or quality of care after the initial HF hospitalization and patient adherence to essential medications may affect 1 year outcome. Of note, within the MAGGIC meta-analysis, there was one Japanese HF registry conducted by Tsutsui et al. that consisted 172 HF patients recruited during the year 1997. There were notable differences in the baseline demographics such as higher age, higher prevalence of atrial fibrillation, and smokers commonly seen in our current registry; however, the 1 year mortality rate did not differ significantly indicating a better prognosis in our database reflecting modern-day HF patients.

Natriuretic peptide-guided treatment of HF has been known to reduce all-cause mortality in relatively young HF patients and overall reduce HF hospitalizations. Although the emergence of other biomarkers such as soluble ST2, growth differentiation factor 15, cystatin-C, galectin-3, and high sensitivity C-reactive protein has slightly shifted physicians away from measuring BNP or N terminal proBNP in recent years, the prognostic value of serum natriuretic peptides remains robust, which has been shown in previous studies. In this study, we observed a significant additive value of discharge BNP and an overall improvement of the MAGGIC score with this modification. This result points to the importance of BNP measurement upon risk prediction as in fact mentioned in the discussion section by Pocock et al. within the original MAGGIC article. Nonetheless, discharge BNP levels should be interpreted with caution because the length of stay is significantly longer in Japan as compared with Western countries. Discharge BNP in Japanese HF patients is likely to reflect patient status after achieving full haemodynamic compensation. Thus, high discharge BNP is likely to indicate a more hazardous state despite rigorous medical attempts to achieve stable status under the Japanese healthcare system. Although the issue of costs associated with BNP

![Figure 3](image-url)
measurements remains an issue, its prognostic importance is robust upon predicting post-discharge mortality beyond racial or ethnic differences. With the widespread use of angiotensin receptor neprilysin inhibitor, the use of N terminal-proBNP over traditional BNP may be more valid in recent days. Nevertheless, our results suggest that future HF risk models ought to incorporate natriuretic peptides as a covariate to meet high performance in various ethnicities.

**Limitations**

There are several limitations to our current study. Although more than 2000 patients were evaluated in the current study, this population may not be representative of the entire Japanese population because the registry was conducted within the metropolitan area or its residing districts of Tokyo. Nevertheless, the model performed modestly in a single-centre NaDEF registry consisted of patients mostly living in Osaka, the second largest city situated in the western part of Japan. Validation of the model may be necessary in other regions or larger sized registries because variation in patient characteristic, treatment, and practice pattern may exist. Second, we inevitably encountered substantial missing data especially for discharge BNP, and the model performance was only assessed for those with complete data without statistical imputation. This may have resulted in overestimation/underestimation of the modified MAGGIC score, although there were no statistical significant differences in the average MAGGIC score between those with and without discharge BNP. Third, we were able to assess model performance for 1 year mortality but not for 3 year
mortality because our database was designed to follow up patients up to 2 years.

**Conclusions**

The performance of the MAGGIC HF risk score is reasonable in the Japanese HF population over a single year time frame. The addition of discharge BNP significantly enhances model discrimination and calibration that was further confirmed in an external validation cohort. Future HF risk models ought to incorporate BNP as a covariate to meet high performance in various ethnicities.

**Conflict of interest**

S.K. received lecture fees from Pfizer Japan Inc. and also received an unrestricted research grant for the Department of Cardiology, Keio University School of Medicine, from Bayer Pharmaceutical Co., Ltd. The authors report no other conflict of interest.

**Author contributions**

M.S., Y.S., and S.K. conceived and designed the research and drafted the manuscript; M.S., Y.S., and S.K. analysed...
References

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. *Eur Heart J* 2014; 35: 2929.

2. Guo Y, Lip GY, Banerjee A. Heart failure in East Asia. *Curr Cardiol Rev* 2013; 9: 112–122.

3. Malhotra R, Bakken K, D’Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. *JACC Heart Failure* 2016; 4: 607–616.

4. Levy WC, Mozaffarian D, Linker DT, Sutrakhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. *Circulation* 2006; 113: 1424–1433.

5. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. *Eur J Heart Fail* 2013; 34: 1404–1413.

6. Sartipy U, Dahlstrom U, Edner M, Lund LH. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. *Eur J Heart Fail* 2014; 16: 173–179.

7. Freed BH, Daruwalla V, Cheng JY, Aguilar FG, Beussink I, Choi A, Klein DA, Dixon D, Baldwin A, Rasmussen-Torvik LJ, Maganti K, Shah SJ. Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strain. *Circ Cardiovas Imaging* 2016; 9: pii: e003754.

8. Kubanek M, Goode KM, Lanska V, Clark AL, Cleland JG. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction. *Eur J Heart Fail* 2009; 11: 367–377.

9. van Veldhuisen DJ, Linsen GC, Jaarsma T, van Gilst WH, Hoeks AW, Tijssen JG, Paulus WJ, Voors AA, Hillegè HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. *J Am Coll Cardiol* 2013; 61: 1498–1506.

10. Troughton R, Michael Felker G, Januzzi JL Jr. Natriuretic peptide-guided heart failure management. *Eur Heart J* 2014; 35: 16–24.

11. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. *J Am Coll Cardiol* 1993; 22: 6a–13a.

12. Akita K, Kohn T, Kohsaka S, Shiraishi Y, Nagatomo Y, Izumi Y, Goda A, Mizuno A, Sawano M, Inohara T, Fukuda K, Yoshikawa T. Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. *Int J Cardiol* 2017; 235: 162–168.

13. Takei M, Kohsaka S, Shiraishi Y, Goda A, Izumi Y, Yagawa M, Mizuno A, Sawano M, Inohara T, Fukuda K, Yoshikawa T. Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. *Circ Heart Fail* 2015; 8: 527–532.

14. Inohara T, Kohsaka S, Shiraishi Y, Goda A, Sawano M, Yagawa M, Mahara K, Fukuda K, Yoshikawa T. Prognostic impact of renal and hepatic dysfunction based on the MELD-XI score in patients with acute heart failure. *Int J Cardiol* 2014; 176: 571–573.

15. Shiraishi Y, Kohsaka S, Abe T, Mizuno A, Goda A, Izumi Y, Yagawa M, Akita K, Sawano M, Inohara T, Takei M, Kohn T, Higuchi S, Yamasoe M, Mahara K, Fukuda K, Yoshikawa T. Validation of the Get With The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. *Am Heart J* 2016; 171: 33–39.

16. Ngai T, Nishimura K, Honna T, Higashiyama A, Sugano Y, Nakai M, Honda S, Ikawaki N, Okada A, Kawakami S, Kanaya T, Asaumi Y, Aiba T, Nishida Y, Kubota Y, Sugiyama D, Okamura T, Noguchi T, Kusano K, Ogawa H, Yasuda S, Anzai T. Prognostic significance of endogenous erythropoietin in long-term outcome of patients with acute decompensated heart failure. *Eur J Heart Fail* 2016; 18: 803–813.

17. Okada A, Sugano Y, Nagai T, Honda Y, Ikawaki N, Nakano H, Takashio S, Honda S, Asaumi Y, Aiba T, Noguchi T, Kusano K, Yasuda S, Anzai T. Usefulness of the direct and/or total bilirubin to predict adverse outcomes in patients with acute decompensated heart failure. *Am J Cardiol* 2017; 119: 2035–2041.

18. Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With The Guidelines program. *Circ Cardiovas Qual Outcomes* 2010; 3: 25–32.

19. Shiraishi Y, Sawano M, Kohn T, Nishiyama T, Maekawa Y, Sano M, Fukuda K, Kohsaka S. Validation of the Seattle Heart Failure Model in Japanese heart failure patients. *Int J Cardiol* 2016; 203: 87–89.

20. Gustafsson F, Torp-Pedersen C, Brendorp B, Seibæk M, Burchardt H, Kober L. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article.

**Table S1.** Baseline characteristics of patients with and without discharge BNP value.

**Figure S1.** Calibration of the MAGGIC score.
left ventricular systolic function. *Eur Heart J* 2003; **24**: 863–870.
21. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, Portmay EL, Marshalko SJ, Radford MJ, Krumholz HM. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. *J Am Coll Cardiol* 2003; **42**: 736–742.
22. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet* 2003; **362**: 759–766.
23. Torp-Pedersen C, Kober L, Carlse JE, Akkan D, Bruun NE, Dacoronias D, Dickstein K, Haghfelt T, Ohlin H, McMurray JJ. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. *Eur J Heart Fail* 2008; **10**: 89–95.
24. Tarantini L, Faggiano P, Senni M, Lucci D, Bertoli D, Porcu M, Opasich C, Tavazzi L, Maggioni AP. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure. *Ital Heart J* 2002; **3**: 656–664.
25. Martinez-Selles M, Garcia Robles JA, Prieto L, Domínguez Munoz M, Frades E, Diaz-Castro O, Almendral J. Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure. *Eur Heart J* 2003; **24**: 2046–2053.
26. Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, Woodward M, Patel A, McMurray J, MacMahon S. Risk prediction in patients with heart failure: a systematic review and analysis. *JACC Heart Failure* 2014; **2**: 440–446.
27. Ouwerkerk RW, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. *JACC Heart Failure* 2014; **2**: 429–436.
28. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. *Am J Cardiol* 2001; **88**: 530–533.
29. Troughton RW, Frampton CM, Brunner-La Rocca HP, Pfisterer M, Eurlings LW, Erntell H, Persson H, O’Connor CM, Moertl D, Karlstrom P, Dahlstrom U, Gaggin HK. Januzzi JL, Berger R, Richards AM, Pinto YM, Nicholls MG. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. *Eur Heart J* 2014; **35**: 1559–1567.
30. Demissel BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Severin TM, Wang Y, Qian M, Teerlink JR, Metra M, Davison BA, Voors AA. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. *Eur J Heart Fail* 2017; **19**: 1001–1010.
31. Yu CM, Sanderson JE. Plasma brain natriuretic peptide—an independent predictor of cardiovascular mortality in acute heart failure. *Eur J Heart Fail* 1999; **1**: 59–65.
32. Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovannazzo P, Carbonieri E, Ceci V, Cerisano S, Barro S, Milani L. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. *J Card Fail* 2005; **11**: 498–503.
33. Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P, Fracassi F, Bordonali T, Milani P, Danesi R, Verzura G, Chiari E, Dei CL. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. *Eur J Heart Fail* 2007; **9**: 776–786.
34. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Isomma S, Metra M, Pascual-Figal D, Laribi S, Logeat D, Nouria S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazaa A. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. *Int J Cardiol* 2013; **168**: 2186–2194.